<<
>>

Литература

Guidelines for the diagnosis and treatment of Chronic Heart Failure: full text (update 2005) The Task Force for the diagnosis and treatment of CHF of the European Society of Cardiology.
Eur Heart J. 2005;26 (22):2472. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure), http: www. acc. org/qual-ityandscience/clinical/guidelines/failure/ update/index, pdf. HFSA 2006 Comprehensive Heart Failure Practice Guideline Journal of Cardiac Failure. 2006;12:el-el22. Национальные рекомендации по диагностике и лечению ХСН (Утверждены съездом кардиологоп РФ в октябре 2003 г.) Журнал Сердечная Недостаточность. 2003;4 (6):276— 297. Агеев Ф.Т., Даниелян М.О., Мареев В. Ю. и др. Больные с хронической сердечной недостаточностью в российской амбулаторной практике: особенности контингента, диагностики и лечения (по материалам исследования ЭПОХА-О-ХСН). Журнал Сердечная недостаточность. 2004;5 (1):4—7. Cleland JG, Swedberg К, Follath F et al. The EuroHeart Failure survey programme a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003;24 (5):442- 463. Мареев В.Ю., Даниелян М. О., Беленков Ю. Н. От имени рабочей группы исследования ЭПОХА—О—ХСН. Сравнительная характеристика больных с ХСН в зависимости от величины ФВ по результатам Российского многоцентрового исследования ЭПОХА—О— ХСН. Журнал Сердечная Недостаточность. 2006;7(4):164-

171. Owan ТЕ, Hodge DO, Herges RM et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355(3):25l-259. Даниелян М. О. Прогноз и лечение хронической сердечной недостаточности (данные 20—и летнего наблюдения).

Автореф. дис. канд. мед. наук. Москва. 2001. Hogg К, Swedberg К, McMurray J. Heart Failure with preserved left ventricular systolic function. Epidemiology, Clinical Characteristics, and

Prognosis. J Am Coll Cardiol. 2004;43 (3):317-327. Cowie MR, Fox KF, Wood DA et al. Hospitalization of patients with heart failure: a population—based study. Eur Heart J. 2002;23 (11):877—885. McAlister FA, Teo KK, Taher M et al. Insights into the contemporary epidemiology and outpatient management of congestive heart failure. Am Heart J. 1999;138 (1 Pt

1):87—94. Агеев Ф.Т. Влияние современных медикаментозных средств на течение заболевания «качество жизни» и прогноз больных с различными стадиями хронической сердечной недостаточности. Автореф. Дисс. Докт., Москва, 1997. Increasing awareness and improving the management of heart failure in Europe: the IMPROVEMENT of HF initiative. The Study Group on Diagnosis of the Working Group on Heart Failure of The European Society of Cardiology. Eur J Heart Fail. 1999; 1 (2): 139-144. Zile MR, Gaasch WH, Carroll JD et al. Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? Circulation. 2001;104(7):779-782. Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J. 2006;27(16):1979-2030. Беленков Ю. H., Мареев В.Ю., Агеев Ф. Т., Даниелян M. О. Первые результаты национального эпидемиологического исследования — эпидемиологическое обследование больных ХСН в реальной клинической практике (по обрашаемости) — ЭПОХА—О—ХСН. Журнал Сердечная Недостаточность. 2003;4 (3):116-121. Агеев Ф.Т., Даниелян М.О., Мареев В.Ю., Беленков Ю.Н.

Больные с хронической сердечной недостаточностью в российской амбулаторной практике: особенности контингента, диагностики и лечения (по материалам исследования ЭПОХА—О—ХСН). Журнал Сердечная Недостаточность. 2004;5 (1):4—7. Беленков Ю. H. Б Мареев В. Ю. Принципы рационального лечения сердечной недостаточности. — М.: «Медиа Медика», 2000. — 266 с. Мареев В. Ю. Фармако—экономическая оценка использования ИАПФ в амбулаторном лечении больных с сердечной недостаточностью (ФАСОН) Журнал Сердечная Недостаточность. 2002;3 (1):38-39. American Heart Association. Heart Disease and Stroke Statistics: 2005 Update. Dallas, Tex; American Heart Association; 2005. Ho KK, Anderson KM, Kannel WB et al. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 1993;88 (1):107—115. Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case—control study. Lancet. 2004;364 (9438):937-952. Wilhelmsen L, Rosengren A, Eriksson H, Lappas G. Heart failure in the general population of men: morbidity, risk factors and prognosis. J Intern Med. 2001;249 (3):253—261.

Effects of treatment on morbidity in hypertension, II: results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA. 1970;213 (7):1143-52. Kostis JB, Davis BR, Cutler J, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA. 1997;278(3):212-216. Baker DW. Prevention of heart failure. J Card Fail. 2002;8 (5):333-346. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42 (6): 1206-1252. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a metaanalysis. Lancet. 2001;358 (9290): 1305—1315. Major outcomes in high—risk hypertensive patients randomized to angiotensin—converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid— Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

JAMA. 2002;288 (23):2981-2997. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood—pressure lowering and low—dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351 (9118): 1755—1762. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascularcomplications in type 2 diabetes: UKPDS 38. BMJ. 1998;317 (7160):703-713. PROGRESS Collaborative Group. Randomized trial of a perindopril — based blood — pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet. 2001;358 (9287): 1033—1041. Izzo JL Jr, Gradman AH. Mechanisms and management of hypertensive heart disease: from left ventricular hypertrophy to heart failure. Med Clin North Am. 2004;88 (5): 1257-1271. Национальные рекомендации по профилактике, диагностике и лечению артериальной гипертонии (Рекомендации разработаны экспертами Всероссийского научного общества кардиологов в 2001 году и утверждены на Российском национальном конгрессе кардиологов 11 октября 2001г., второй пересмотр Рекомендаций осуществлен в 2004г.) http: www. cardiosite. ru/ medical/recom—artgip. asp. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo— controlled, multicentre trial (the EUROPA study). Lancet. 2003;362 (9386):782-788. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin— converting—enzyme inhibitor, ramipril, on cardiovascular events in high—risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145-153. Timolol—induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 1981;304 (14):801-807. Chadda K, Goldstein S, Byington R, Curb JD. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure.
Circulation. 1986;73 (3):503—510. Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival And Ventricular Enlargement Trial. The SAVE Investigators. N Engl J Med. 1992;327 (10):669-677. GISSI—3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6— week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Soprawivenza nell’infarto Miocardico. Lancet. 1994;343 (8906): 1115— 1122. ISIS—4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS—4: a

randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS—4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet. 1995 ;345 (8951):669-685. Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20):1893-1906. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348 (14):1309-1321. Vantrimpont P, Rouleau JL, Wun CC, et al. Additive beneficial effects of beta-blockers to angiotensin— converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators. J Am Coll Cardiol. 1997;29 (2):229-236. Jones CG, Cleland JG. Meeting report: the LIDO, HOPE, MOXCON and WASH studies: Heart Outcomes Prevention Evaluation. The Warfarin/Aspirin Study of Heart Failure. Eur J Heart Fail. 1999; 1 (4):425-431. Massie B. Final results jf the warfarin and antiplatelet trial in chronic heart failure (WATCH): a randomized comparison ofwarfarin, aspirin and clopidogrel. J Card Fail. 2004; 10 (2):101—112.

Kjekshus J, Pedersen TR, Olsson AG et al. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail. 1997;3 (4):249-

254. Lewis SJ, Moye LA, Sacks FM et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range: Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med. 1998;129 (9):681-689. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long—Term Intervention with Pravastatin in lschaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339 (19):1349—1357. Диагностика и лечение стабильной стенокардии. Российские рекомендации (Разработаны Комитетом экспертов Всероссийского научного общества кардиологов) http: www. cardiosite. ru/medical/recom—stabsten. asp. Диагностика и коррекция нарушений липид-ного обмена с целью профилактики и лечения атеросклероза (Разработаны Комитетом экспертов Всероссийского научного общества кардиологов) http: www. cardiosite. ru/medical/recom—lipid, asp.

Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996;275 (20):1557-1562. Мареев В.Ю., Беленков Ю. Н. Хроническая сердечная недостаточность и инсулиннеза-висимый сахарный диабет: случайная связь или закономерность? Тер. Архив. 2003;75 (10):5-10. Ильина А. В., Мареев В. Ю., Герасимова В. В. и соавт. Эффективность терапии ИАПФ фозиноприлом больных с ХСН в сочетании с сахарным диабетом II типа (по материалам исследования ФАСОН) Журнал Сердечная Недостаточность. 2005;6 (5): 181 — 185. Krumholz HM, Chen YT, Wang Y et al. Predictors of readmission among elderly survivors of admission with heart failure. Am Heart J. 2000;139(1 Pt 1):72—77. Shindler DM, Kostis JB, Yusuf S et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol. 1996;77 (11): 1017—1020. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin—converting—enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329(20):1456-1462. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000;355 (9200):253-259. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345 (12):861-869. Berl T, Hunsicker LG, Lewis J В et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med. 2003; 138 (7):542-549. Effect of intensive blood—glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352 (9131):854-865. Barzilay JI, Pressel S, Davis BR, et al. Risk and impact of incident glucose disorders in hypertensive older adults treated with an ACE

inhibitor, a diuretic, or a calcium channel blocker: a report from the ALLHAT trial. ALLHAT Collaborative Research Group. Am J Hypertens. 2004; 17 (5, part 2 of 2): 1A. Bonow RO, Carabello B, de Leon AC Jr et al. Guidelines for the management of patients with valvular heart disease: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). Circulation. 1998;98

(18):1949-1984. Bach DS, Boiling SF. Improvement following correction of secondary mitral regurgitation in end—stage cardiomyopathy with mitral annuloplasty. Am J Cardiol. 1996;78 (8):966-969. Greenberg B, Massie B, Bristow JD et al. Long—term vasodilator therapy of chronic aortic insufficiency. A randomized double—blinded, placebo-controlled clinical trial. Circulation. 1988;78 (1):92—103. Scognamiglio R, Rahimtoola SH, Fasoli G et al. Nifedipine in asymptomatic patients with severe aortic regurgitation and normal left ventricular function. N Engl J Med. 1994:331 (11):689-694. Мареев В.Ю., Даниелян M. О. Недостаточность митрального клапана в терапевтической клинике. Русский медицинский журнал. 1999;7(15):706-722. Kenchaiah S, Evans JC, Levy D et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347 (5):358-359. Мареев В.Ю. Основные достижения в области понимания, диагностики и лечения ХСН в 2003 г (часть 1). Журнал Сердечная Недостаточность. 2004;5 (1):25—31. Anker SD, Pomkowski P, Varney S.Wasting as independent risk factor of survival in chronic heart failure. Lancet. 1997;349 (9058):1050-1053. Anker SD, Coats Al. Cachexia in heart failure is bad for you. Eur Heart J. 1998;19 (2):191-193. Anker SD, von Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart. 2004;90 (4):464- 470. Von Haehling S, Genth-Zotz S, Anker SD, Volk HD. Cachexia: a therapeutic approach beyond cytokine antagonism. Int J Cardiol. 2002;85 (1):173—183. Cicoira M et al. Growth hormone resistance in chronic heart failure and its therapeutic implications. J Card Fail. 2003;9 (3):219-226. Pasini E, Aquilani R, Gheorghiade M, Dioguardi

FS. Malnutrition, muscle wasting and cachexia in chronic heart failure: the nutritional approach. Ital Heart J. 2003;4 :232-235. Heymsfield SB, Casper K. Congestive heart failure: clinical management by use of continuos nasoenteric feeding. Am J Clin Nutr. 1989;50 (3):539-544. Paccagnella A, Cali MA, Caenaro G et al. Cardiac cachexia: preoperative and postoperative nutrition management. J Parenter Enteral Nutr. 1994;18 (5):409—416. Шестопалов A. E., Матраева Ю.С., Дьяков А. Ю. и др. Нутритивная поддержка и коррекция метаболических нарушений у больных с ишемической болезнью сердца и дефицитом тощей массы тела при хирургической реваскуляризации миокарда. Сердечная Недостаточность. 2001;2 (3): 108-112. Арутюнов Г. П., Костюкевич О. И. Питание больных с хронической сердечной недостаточностью, проблемы нутритивной поддержки, решенные и нерешенные аспекты. Журнал Сердечная Недостаточность. 2002;3 :245-248. Руководство по парентеральному и энтераль-ному питанию под редакцией Хорошилова И.Е. — Санкт- Петербург, 2001. — 179-181с. Арутюнов Г. П., Костюкевич О. И., Рылова Н.В. Применение сбалансированной смеси Пептамен для энтерального питания в лечении больных с ХСН. Журнал Сердечная Недостаточность. 2002;3 (5):221—225. Freeman LM, Roubenoff R.The nutrition implication of cardiac cachexia. Nutr Rev. 1994;52(10):340-347. Paccagnella A, Cali MA, Caenaro G et al. Cardiac

cachexia:              preoperative              and              postoperative nutrition

management. J Parent Enter Nutr. 1994;18(5):409-416. Smith J, Redd S. Enteral formulation designed for cardiac cachexia. J Parent Enter Nutr. 1980;4:595A. Taenaka N, Yagi M. Nutritional support in cardiac failure. Nippon Rinsho. 2001;59 Suppl 5:434-437.

Арутюнов Г. П., Костюкевич О.И., Рылова Н.В. и др. Влияние энтерального питания на толерантность к физическим нагрузкам и клиническую картину у больных с ХСН III— IV функционального класса. Кардиология. 2003;5. Арутюнов Г. П., Костюкевич О.И., Рылова Н.В. Питание больных с ХСН: проблемы нутритивной поддержки (решенные и нерешенные аспекты) Тер. Архив. 2003;75 (8):88-92. Fukui К, Suzuki S, Takaya S, Takeuchi K. Nutritional support in cardiac cachexia. Nippon Rinsho. 2001 ;59 Suppl 5:438-441. Sole MJ, JeejeebhoyKN. Conditioned nutritional requirements and the patogenesus and treatment of myocardial failure. Curr Opin Clin Nutr Metab Care. 2000;3(6):417-424. Walsh CR,LarsonMG, Evans JCet al. Alcoholconsumption and risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med. 2002;136(3):181-191. Abramson JL, Williams SA, Krumholz HM, Vaccarino V. Moderate alcohol consumption and risk of heart failure among older persons. JAMA. 2001;285 (15): 1971 — 1977. Осипова И. В., Ефремушкин ГГ., Березенко Е.А. Длительные физические тренировки в комплексном лечении пожилых больных с хронической сердечной недостаточностью. Журнал Сердечная Недостаточность. 2002;3 (5):218—221. Арутюнов Г. П. Вопросы немедикаментозного лечения пациентов, страдающих сердечной недостаточностью. Сердечная недостаточность. 2001;2 (1):35—36. Осипова И. В. «Свободный выбор нагрузки» физических тренировок — эффективный метод лечения хронической сердечной недостаточности. Сердечная недостаточность. 2001;2 (4):176—180. Exercise Standards. A statement for health professionals from the American Heart Association. Special Report. Circulation. 1990;82 (6):2291-2292. Gibbons RJ, Balady GJ, Beasley JW et al. ACC/AHA guidelines for exercise testing: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). Circulation. 1997;96(l):345-354. Аронов Д. М. Кардиологическая реабилитация на рубеже веков. Сердце. 2002; 1 (3): 123—125. Осипова И. В. Длительныефизическиетрени-ровки в комплексном лечении пожилых больных с хронической сердечной недостаточностью. Журнал Сердечная Недостаточность. 2002;3(5):218-220. Sullivan MJ, Higginbotham MB, Cobb F. R. Exercise training in patients with severe left ventricular dysfunction: hemodynamic and metabolic effects. Circulation. 1988;78 (3):506-515. Cowie MR, Mosterd A, Wood DA et al. The epidemiology of heart failure. Eur Heart J. 1997;18(2):208-225. Spencer FA, MeyerTE, Goldberg RJ. Twenty year trends (1975-1995) in the incidence, in—hospital and long—term death rates associated with heart failure complicating acute myocardial infarction. J Am Coll Cardiol. 1999;34 : 1378-1387. Khand A, Gemmel I, Clark AL, Cleland JGF. Is the prognosis of heart failure improving? J Am Coll Cardiol. 2000;36 (7):2284-2286. Jong P, Vowinckel E, Liu PP et al. Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population—based study. Arch Intern Med. 2002;162 (15): 1689— 1694. Stromberg A. The crucial role of patient education in heart failure. Eur J Heart Fail. 2005;7 (3):363-369. Агеев Ф.Т, Мареев В.Ю., Середенина E. M., Беленков Ю. H. Перспективы внедрения специализированных форм активного амбулаторного ведения больных с сердечной недостаточностью: структура, методика и предварительные результаты Российской программы «ШАНС». Сердечная недостаточность. 2004;5(6):268-271. GrangerCB, McMurray JJ, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left—ventricular systolic function intolerant to angiotensin—converting-enzyme inhibitors: the CHARM- Alternative trial. Lancet. 2003;362 (9386):772-776. McMurray JJ, Ostergren J, Swedberg К et al. Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function taking angiotensin—convertingenzyme inhibitors: the CHARM- Added trial. Lancet. 2003;362(9386):767-771. Yusuf S, Pfeffer MA, Swedberg К et al. Effects of candesartan in patients with chronic heart failure and preserved left—ventricular ejection fraction: the CHARM Preserved Trial. Lancet. 2003;362 (9386):777-781. Cohn JN, Archibald DG, Ziesche S et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;314 (24): 1547—1552. Taylor AL, Ziesche S, Yancy С et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351 (20):2049-2057. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341 (10):709-717. Cohn JN, Ziesche S, Smith R et al. Effect of the calcium antagonist felodipine as supplementary

vasodilator therapy in patients with chronic heart failure treated with enalapril: V—HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation. 1997;96 (3):856-863. Thackray S, Witte K, Clark AL, Cleland JG. Clinical trials update: OPTIME-CHF, PRAISE-2, ALL-HAT. Eur J Heart Fail. 2000;2 (2):209-212. Фомин И. В. Как мы лечим АГ и ХСН в реальной практике: уроки Российского исследования ЭПОХА Журнал Сердечная недостаточность. 2004;5 (2):53—54. Komajda M, Follath F, Swedberg К et al. The EuroHeart Failure Survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J. 2003;24 (5):464-474. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J. 1997:18 (10):1569-1582. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J. 2001;22(7):554-572.

Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin—convertingenzyme inhibitors on mortality and morbidity in patients with heart failure JAMA. 1995;273 (18): 1450—1456. Беленков Ю. H., Мареев В.Ю., Агеев Ф. Т. -Медикаментозные пути улучшения прогноза больных с хронической сердечной недочста-точностью. — М.: Инсайт, 1997. — 77с. NSAIDs and heart failure. Prescrire Int. 2001; 10 (56):182-183. BankAJ, KuboSH, RectorTSetal. Localforearm vasodilation with intra—arterial administration of enalaprilat in humans. Clin Pharmacol Ther. 1991 ;50 (3):314—321. Мареев В.Ю., Агеев Ф. Т., Арутюнов Е П. и др. Применение диклофенака и целебрекса у пациентов с артериальной гипертонией и болями в нижней части спины на фоне гипотензивной терапии аккупро или норвас- ком (исследование ДОЦЕНТ). Журнал Сердечная недостаточность. 2005;6 (33):204-208. Hall D, Zeitler H, Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol. 1992;20 (7): 1549-1555. Мареев В. Ю. Взаимодействие лекарственных средств при лечении больных с сердечно-сосудистыми заболеваниями. 1. Ингибиторы АПФ и аспирин. Есть ли повод для тревоги? Сердце. 2002; 1 (4):161—168. Al Khadra AS, Salem DN, Rand WM et al. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J Am Coll Cardiol. 1998;31 (2):419-425. Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Am J Cardiol. 1997;79(2):115-119. Kindsvater S, Leclerc K, Ward J. Effects of coadministration of aspirin or clopidogrel on exercise testing in patients with heart failure receiving angiotensin—converting enzyme inhibitors. Am J Cardiol. 2003;9I (11): 1350— 1352. Spaulding C, Charbonnier B, Cohen—Sola! A et al. Acute hemodynamic interaction of aspirin and ticlopidine with enalapril: results of a double-blind, randomized comparative trial. Circulation. 1998;98 (8):757-765. Лопатин Ю. М. Совместное применение аспирина и ингибиторов АПФ при ХСН: позиция «За». Журнал Сердечная недостаточность. 2003;4 (19):149—152. Мареев В. Ю. Аспирин при хронической сердечной недостаточности. Взаимодействие аспирина с основными средствами лечения декомпенсации. Журнал Сердечная недостаточность. 2003;4 (19):153-157. Тео КК, Yusuf S, Pfeffer M et al. Effects of long-term treatment with angiotensin-converting— enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet. 2002;360 (9339): 1037-1043. Harjai K.J, Solis S, Prasad A, Loupe J. Use of aspirin in conjunction with angiotensin-converting enzyme inhibitors does not worsen long—term survival in heart failure. Int J Cardiol. 2003;88(2-3):207-214. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324 (7329):71-86. Shekelle PG, Rich MW, Morton SC. Efficacy of angiotensin-converting enzyme inhibitors and beta- blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status. A meta-analysis of major clinical trials. J Am Coll Cardiol. 2003;41 (9):1529—1538. Effect of enalapril on mortality and the development of heart failure m asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD investigators. N Engl J Med. 1992;327 (10):685—691. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD investigators. N Engl J Med. 1991 ;325 (5):293-302. Cohn Jn, Johnson G, Ziesche S et al. A comparison of enalapril with hydralazine—isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325 (5):303-310. McKelvie RS, Rouleau J-L, White М et al. Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure. Eur Heart J. 2003;24 (19): 1727—1734. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med. 1987;316 (23): 1429-1435. Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high—risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002;360 (9335):752-760. Kleber FX, Doering W. Prognosis of mild chronic heart failure: effects of the ACE inhibitor captopril. Herz. 1991; 16 Spec No 1:283-293. Kleber FX, Niemller L.Long—term survival in the Munich Mild Heart Failure Trial (MHFT). Am J Cardiol. 1993;7I (13): 1237-1239. A placebo—controlled trial of captopril in refractory chronic congestive heart failure. Captopril Multicenter Research Group. J Am Coll Cardiol. 1983;2 (4):755-763. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial: the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355 (9215):15S2—1587. Скворцов А.А., Насонова С.Н., Сычев А.В. и др. Комбинированное применение ингибитора ангиотен- зинпревращающего фермента квинаприла и блокатора рецепторов 1-го типа к ангиотензину II валсартана у больных с умеренной хронической сердечной недостаточностью: возможно ли повышение степени ней- рогормональной блокады и улучшение параметров суточной вариабельности ритма сердца по сравнению с действием ионотерапии (по результатам исследования САДКО— ХСН). Тер. Архив. 2005;77 (1):34—43. Borghi С, Marino Р, Zardini Р et al. Short-and long— term effects of early fosinopril administration in patients with acute anterior myocardial infarction undergoing intravenous thrombolysis: results from the Fosinopril in Acute Myocardial Infarction Study. FAMIS Working Party. Am Heart J. 1998;136 (2):213—225.

Erhardt L, MacLean A, Ilgenfritz J et al. Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Eur Heart J. 1995;16 : 1892—1899. Brown EG, Cheu PH, MacLean A et al. Effects of fosinopril on exercise tolerance and clinical deterioration in patients with chronic congestive heart failure not taking digitalis. Am J Cardiol. 1995;75 (8):596-600. Zannad F, Chati Z, Guest M et al. Differential effect of fosinopril end enalapril in patients with mild to moderate CHE Am Heart J. 1998;136 (4 Pt 1):672—680. Cleland JG, Tendera M, Adamus J et al. PEP-CHF Investigators The perindopril in elderly people with chronic heart failure (PEP—CHF) study. Eur Heart J. 2006;27

(19):2338-2345. Massie BM, Armstrong PW, Cleland JG et al. Toleration of high doses of angiotensin— converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial: the Assessment of Treatment with Lisinopril and Survival. Arch Intern Med. 2001;161 (2):165-171. Giles TD, Katz R, Sullivan JM et al. Short- and long— acting angiotensin—converting enzyme inhibitors: a randomized trial of lisinopril versus captopril in the treatment of congestive heart failure. J Am Coll Cardiol. 1989;13 (6):1240-1247. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. I993;342 (8875):821 —828. Riegger GA. Effects of quinapril on exercise tolerance in patients with mild to moderate heart failure. Eur Heart J. 1991:12 (6):705-7l 1. Pflugfelder PW, Baird MG, Tonkon MJ et al. Clinical consequences of angiotensin—converting enzyme inhibitor withdrawal in chronic heart failure: a double— blind, placebo-controlled study of quinapril. J Am Coll Cardiol. 1993;22 (6):1557—1563. Beynon JH, Pathy MS. An open, parallel group comparison of quinapril and captopril, when added to diuretic therapy, in the treatment of elderly patients with heartfailure. Curr Med Res Opin. 1997;13(10):583-592. Widimsky J, Kremer HJ, Jerie P et al. Czech and Slovak spirapril intervention study (CASSIS). A randomized, placebo and active—controlled, double—blind multicentre trial in patients with congestive heart failure. Eur J Clin Pharmacol. 1995;49(l-2):95-102. Мареев В.Ю., Ольбинская Л. И., Мартынов А. И. Проспективное, многоцентровое, открытое исследование эффективности и переносимости КВАдроприла у больных с Недостаточностью Кровообращения, обусловленной ишемической болезнью сердца и дилаташ- юнной кардиомиопатией (Исследование КВАНК) Журнал Сердечная Недостаточность. 2007;8 (1). Sica DA, Cutler RE, Parmer RJ et al. Comparison of the steady—state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency. Clin Pharmacokinet. 1991;20(5):420-427. Greenbaum R, Zucchelli P, Caspi A et al. Comparison of the pharmacokinetics of fosinopril with enalaprilat and lisinopril in patients with CHF and chronic renal insufficiency. Br J Clin Pharmacol. 2000;49 (1):23—31. Ferrari R. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Arch Intern Med. 2006;166(6):659-666. Braunwald E, Domanski MJ, Fowler SE et al. Angiotensin— converting—enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351 (20):2058-2068. Мареев В.Ю. Ингибиторы ангиотензин превращающего фермента в лечении больных с коронарной болезнью сердца. Взгляд 2003 года. «Кардиология». 2003;42 (12):3—10. Packer M, Lee WH, Medina N et al. Functional renal insufficiency during long—term therapy with captopril and enalapril in severe chronic heart failure. Ann Intern Med. 1987; 106 (3):346-354. Packer M, Lee WH, Kessler PD et al. Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition in severe chronic heart failure. J Am Coll Cardiol. 1987; 10 (4):837-844. David D, Jallad N, Germino W et al. A comparison of the cough profile of fosinopril and enalapril in hypertensive patients with history of ACE inhibitor — associated cough. Am J Ther. 1995;2(10):806-813. Mac Fadyen RJ, Lees KR, Reid JL. Differences in first—dose response of angiotenzine converting enzyme inhibition in congestive heart failure. Br Heart J. 1991:66 (3):206—211. Navookarasu NT, Rahman A, Abdullah I et al. First— dose responce to angiotensin converting enzyme inhibition in chronic cardiac failure: a Malaysian experience. Int J Clin Pract. 1999;53 (1):25—30. The NETWORK Investigators. Clinical outcome with enalapril in symptomatic chronic heart failure: a dose comparison. Eur Heart J. 1998; 19 (3):481-489. Noble S, Sorkin EM. Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension. Drugs. 1995;49 (5):750-766. Cohn JN, Levine ТВ, Olivari MT et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;3U

(13):819—823. Francis GS, Benedict C, Johnstone DE et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82 (5):1724-1729. Беленков Ю.Н., Мареев В.Ю., Агеев Ф. Т. Хроническая сердечная недостаточность. Избранные лекции по кардиологии. — М.: ГЭОТАР-Медиа, 2006-432 с. Мухарлямов Н. M, Наумов В. Г., Орлова А. И Сочета- ное применение бета — адреноблока-торов в комбинации с сердечными гликози-дами для лечения больных с дилатационны-ми кардиомиопатиями и сердечной недостаточностью. Бюлл. ВКНЦ, 1978;1:78-82. Communal С, Singh К, Pimentel DR, Colucci WS. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Circulation. 1998;98 (13):1329—1334. Беленков Ю.Н., Мареев В.Ю., Скворцов А.А. и др. Клинико—гемодинамические и нейрогуморальные

эффекты длительной терапии бета—адреноблокато- ром бисопроло-лом больных с тяжелой хронической сердечной недостаточностью. Кардиология. 2003;43 (10);11—22. Metra M, Nardi M, Giubbini R, Dei CL. Effects of short— and long—term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in

patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. I994;24 (7): 1678-1687. Olsen SL, Gilbert EM, Renlund DC et al. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol. 1995;25 (6): 1225—1231. Беленков Ю.Н., Мареев В. Ю., Скворцов А. А. и соавт. Эналаприл против Карведилола. Сравнительное рандомизирован—ное исследование у больных с хронической сердечной недостаточностью (ЭКСТАЗ). Сердечная Недостаточность. 2001 ;2 (2):84-91. Packer M, Bristow MR, Cohn JN et al, for the U.S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334 (21): 1349—1355. Randomised, placebo—controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. Lancet. 1997;349 (9049):375-380. The Cardiac Insufficiency Bisoprolol Study II (CIBIS- : arandomizedtrial. Lancet. 1999;353 (9146):9-13. MERIT-HF Study Group. Effects of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized International Trial in Congestive Heart Failure (MERIT— HF). Lancet. 1999;353(9169):2001-2007. Packer M, Coats AJ, Fowler MB et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344 (22):1651-1658. Mareev V, Lopatin Yu, Pervez Gh. Possible mechanisms of positive beta-blocker effects in the treatment of dilated cardiomyopathy. Eur Heart J. 1993:14:94 Gaffney ТЕ, Braunwald E. Importance of the adrenergic nervous system in the support of circulatory function in patients with congestive heart failure. Am J Med. 1963;34:320-324. Cleland JG, Pennell DJ, Ray SG etal. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. Lancet. 2003;362 (9377):14-21. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet. 1993;342 (8885): 1441-1446. Poole-Wilson PA, Swedberg K, Cleland JG et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart

failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362 (9377):7—13. Flather MD, Shibata MC, Coats AJ et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26 (3):215-225. Willenheimer R, van Veldhuisen DJ, Silke В et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) Circulation. 2005;112 (16):2426-2435. Erdmann E, Lechat P, Verkenne P, Wiemann H. Results from post—hoc analyses of the CIBIS II trial: effect of bisoprolol in high—risk patient groups with chronic heart failure. Eur J Heart Fail. 2001 ;3 (4):469-479. Deedwania PC, Gottlieb S, Ghali JK et al. Efficacy, safety and tolerability ofbeta—adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure. Eur Heart J. 2004;25 lt;15):1300—1309. Middeljans-Tijssen CW, Jansen RW. Elderly heart failure patients and the role of beta— blockertherapy. Tijdschr Gerontol Geriatr. 2006;37 (2):67-77. Ghali JK; Pi a IL;. Gottlieb SS et al. Metoprolol CR/ XL in Female Patients With Heart Failure Analysis of the Experience in Metoprolol Extended—Release Randomized Intervention Trial in Heart Failure (MERIT-HF). Circulation. 2002:105 (13):1585—1591. Waagstein F, Caidahl K, Wallentin I et al. Long-term beta—blockade in dilated cardiomyopathy: effects of short— and long—term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation. 1989;80(3):551-563. Gattis WA, O'Connor CM, Leimberger JD et al. Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure. Am J Cardiol. 2003;91

(2):169-174. Dorow P, Thalhofer S, Bethge H et al. Long-term treatment of angina pectoris with bisoprolol or atenolol in patients with chronic obstructive bronchitis: a randomized, double—blind crossover study. J Cardiovasc Pharmacol. 1990;16 Suppl 5: S36-44. Bakris GL, Fonseca V, Katholi RE et al. Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension. 2005;46 (6): 1309-15 Follath F, Cleland JG, Just H et al. Efficacy and

safety of intravenous levosimendan compared with dobutamine in severe low—output heart failure (The LIDO study): A randomizes double— blind trial. Lancet. 2002;360 (9328): 196-202. Виноградов А. В. Мочегонные средства в клинике внутренних болезней. — М.: Медицина, 1969.- 151 с. Мухарлямов Н.М., Мареев В. Ю. Лечение хронической сердечной недостаточности. — М.: Медицина, 1985. — 207 с. Kjekshus J, Swedberg K.Tolerability of enalapril in congestive heart failure. Am J Cardiol. 1988;62 (2):67A- 72A. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation. I990;82 (5): 1730-1736. Ljungman S, Kjekshus J, Swedberg K. Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). Am J Cardiol. 1992;70 (4):479-487.

Svensson M, Gustafsson F, Galatius S et al. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Fail. 2004; 10 (4):297-303. Juurlink DN, Mamdani MM, Lee DS et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351

(6):543—551. McMurray JJV, O'Meara E.Treatment of Heart Failure with Spironolactone — Trial and Tribulations. N Engl J Med. 2004;351 (6):526-528. Cody RJ, Kubo SH, Pickworth KK. Diuretic treatment for the sodium retention of congestive heart failure. Arch Intern Med. 1994;154 (17):1905-1914. Patterson JH, Adams KF Jr, Applefeld MM et al. for the Torsemide Investigators Group. Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Pharmacotherapy. 1994; 14 (5):514—521. Brater DC. Diuretic therapy. N Engl J Med. 1998;339(6):387-395. Brater DC, ChennavasinR Seiwell R. Furosemide in patients with heart failure: shift in dose-response curves. Clin Pharmacol Ther. 1980;28 (2):182-186. Vasko MR, Cartwright DB, Knochel JP et al. Furosemide absorption altered in decompensated congestive heart failure. Ann Intern Med.

1985;102(3):314-318. Dormans TP, van Meyel JJ, Gerlag PG et al. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol. 1996;28 (2):376-382. Vargo DL, Kramer WG, Black PK et al. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther. 1995;57 (6):601-609. Brater D.Torasemid: pharmacokinetic and clinical efficacy. Eur J Heart Fail. 2001;3 (Suppl G):19-24. Fortuno A, Muniz P, Ravassa S et al. Torasemide inhibits angiotensin II—induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats. Hypertension. 1999;34 (1):138—143. Yamato M, Sasaki T, Honda К et al. Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. Circ J. 2003;67 (5):384- 390. М Her K, Gamba G, Jaquet F, Hess B. Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV—efficacy and quality of life. Eur J Heart Fail. 2003;5 (6):793-801. Stroupe KT, Forthofer MM, Brater DC, Murray MD. Healthcare costs of patients with heart failure treated with torasemide or furosemide. Pharmacoeconomics. 2000;17

(5):429-440. Cosin J, Diez J, Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail. 2002;4(4):507- 513 Jones PW, Greenstone M. Carbonic anhydrase inhibitors for hypercapnic ventilatory failure in chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2001;(1): CD002881. Philippi H, Bieber I, Reitter B. — Acetazolamide treatment for infantile central sleep apnea. Drugs.2001;61

(2):237-25I. Javaheri S. Acetazolamide improves central sleep apnea in heart failure: a double—blind, prospective study. Am J Respir Crit Care Med. 2006;173(2):234-237. Cleland JG, Coletta AR Nikitin NP et al. Clinical trials update from the American College of Cardiology: Darbepoetin alfa, ASTEROID, UNIVERSE, paediatric carvedilol, UNLOAD and ICELAND. Eur J Heart Fail. 2006;8 (3):326-329. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med. 1997;336 (8):525—533. Uretsky BF, Young JB, Shahidi FE et al. for the PROVED Investigative Group. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. J Am Coll Cardiol. 1993;22 (4):955-562. Packer M, Gheorghiade M, Young JB et al. Withdrawal

of digoxin from patients with chronic heart failure treated with angiotensin—              converting—enzyme              inhibitors:

RADIANCE Study. N Engl J Med. 1993;329 (l):l-7. Gheorghiade M, Adams KF Jr, Colucci WS. Digoxin in the management of cardiovascular disorders. Circulation. 2004; 109 (24):2959-2964. Akera T, Baskin SI, Tobin T, Brody FM. Ouabain: temporal relationship between the inotropic effect and the in vitro binding to, and dissociation from, (Na++ K+)—activated AFPase. Naunyn Schmiedebergs Arch Pharmacol. 1973;277 (2):151—162. Ferguson DW, Berg WJ, Sanders JS et al. Sympathoinhibitory responses to digitalis glycosides in heart failure patients: direct evidence from sympathetic neural recordings. Circulation. 1989;80(l):65-77. Gheorghiade M, Ferguson D. Digoxin: a neurohormone] modulator in heart failure? Circulation. 1991;84 (5):2181— 2186. Нарусов О.Ю., Мареев В. Ю., Скворцов А. А. и др. Клинические, гемодинамические и нейрогормональ- ные эффекты дигоксина у больных с ХСН Серд Недостаточность, 2000;! (1):26—30. Rathore SS, Curtis JP, Wang Y et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;289 (7):871—878. Adams KF, Patterson JH, Gattis WA et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J Am Coll Cardiol. 2005;46 (3):497-504. Cohn JN, Tognoni G. A randomized trial of the angiotensin—receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001 ;345 (23):1667-1675. Maggioni AP, Anand I, Gottlieb SO et al. Effects of Valsartan on Morbidity and Mortality in Patients With Heart Failure Not Receiving Angiotensin—Converting Enzyme Inhibitors J Am Coll Cardiol. 2002;40 (8): 1414—1421. Wong M, Staszewsky L, Latini R et al. Valsartan benefits left ventricular structure and function in heart failure: Val—HeFF echocardiographic study. J Am Coll Cardiol. 2002;40 (5):970-975. Скворцов А. А., Насонова С. Н,, Сычев АВ и др. Эффекты длительной терапии ингибитором ангиотен- зинпревращающекго фермента квинаприлом, антаго

нистом рецепторов к ангиотешину II и комбинацией квинаприла и валсартана у больных с умеренной хронической сердечной недостаточности. Основные результаты исследования САДКО—ХСН. Кардиология. 2006;46 (1):33-51. Скворцов A. A., Мареев В. Ю., Насонова С. Н. и др Рекомендована ли тройная комбинация нейрогормол- нальных модуляторов для лечения умеренной и т тяжелой ХСН? (результаты исследования САДКО—ХСН). Fep. Архив. 2006;78(8):14-20. Haehling S, Okonko DO, Anker SD. Statins: a treatment option for chronic heart failure? Heart Fail Monit. 2004;4 (3):90-97. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335 (14): 1001 — 1009. Mikhailidis DP, Werzbicki AS. The Greak atorvastatin and coronary heart disease evaluation (GREACE) study — CurrMed Res and Opin. 2002;18(4):220-228. Nul D, Fernandez A, Zambrano С et al. Statins

and mortality in congestive heart failure:              benefit

beyond cholesterol reduction? J Am Coll Cardiol. 2005;45(supplA):851-854. Jaganmohan S, Khurana V. Statins improve survival in patients with congestive heart failure: a study on 32000 US veterans. J Am Coll Cardiol. 2005;45(supplA):854-857. Kjekshus J, Dunselman P, Blideskog M et al. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): Study design and baseline characteristics. Eur J Heart Fail. 2005;7

(6):1059-1069. Favazzi L, Tognoni G, Franzosi MF et al. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n—3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail. 2004;6 (5):635—641. Horwich FB, MacLellan R, Fonarow GC. Statin therapy is associated with improved survival in ischemic and non— ischemic heart failure. J Am Coll Cardiol. 2004;43 (4):642-648. Ray GR, G ong Y, Sykora K, Fu JV. Statin use and survival outcomes in elderly patients with heart failure. Arch Intern Med. 2005;165:62-67. J LiaoK. Statin therapy for cardiac hypertrophy and heart failure. J Investig Med. 2004;52:248-253 Gao L, Wang W, Li YL et al. Simvastatin therapy normalizes sympathetic neural control in experimental heart failure: roles of angiotensin II type 1 receptors and NAD (P) Н oxidase. Circulation. 2005;112 (12): 1763—1770 Pliquett RU, Cornish KG, Pettier JD et al. Simvastatin Normalizes Autonomic Neural Control in Experimental Heart Failure. Circulation. 2003:107 (19):2493-2498. Von Haehling S, Anker SD, Bassrnge E. Statins and role of nitric oxide in chronic heart failure. Heart Fail Rev. 2003;8 (1):99—106. NodeK,FujitaM,KitakazeMetal. Short—termstatin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation. 2003;108 (7):839-843. Thomas H, Muhlestein JB, Carlquist JF et al. A cholesterol paradox in congestive heart failure survival? J Am Call Cardiol. 2005;45 (suppl A):851-855. Horwich B, Hamilton MA, Maclellan WR, Fonarow GC. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail. 2002;8 (4):216-224. Rauchhaus M, Clark AL, Doehner W et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol. 2003;42 (11): 1933-1940. Dunkman WB, Johnson GR, Carson PE et al, for the V—HeFT VA Cooperative Studies Group. Incidence of thromboembolic events in congestive heart failure. Circulation. 1993;87 (6 Suppl): VI94-101. Dunkman WB. Thromboembolism and antithrombotic therapy in congestive heart failure. J Cardiovasc Risk. 1995;2 (2):107—117. Katz SD. Left ventricular thrombus and the incidence of thromboembolism in patients with congestive heart failure: can clinical factors identify patients at increased risk? J Cardiovasc Risk. 1995;2(5):97-102. Cioffi G, Pozzoli M, Forni G et al. Systemic thromboembolism in chronic heart failure: a prospective study in 406 patients. Eur Heart J. 1996;17 (9):1381—1389. FusterV, Gersh BJ, Giuliani ER et al. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol. 1981;47 (3):525—531. Stratton JR, Nemanich JW, Johannessen KA, Resnick AD. Fate of left ventricular thrombi in patients with remote myocardial infarction or idiopathic cardiomyopathy. Circulation. 1988;78 (6):1388-1393. Samama MM, Cohen AT, Darmon JY et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999;341 (11):793-800. Turpie AG. Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. Am J Cardiol. 2000;86 (12B):48M-52M. Leizorovicz A, Cohen AT, Turpie AG. G et al. randomized placebo controlled trial of dalteparin for the prevention of venous thromboembolism in 3706 acutely 111 medical patients: the PREVENT medical thromboprophylaxis study Supplement to the Journal of Thrombosis and Haemostasis July. 2003 (ISSN 17403340). Abstract OC396. Ageno W, Turpie AG. Clinical trials of deep vein thrombosis prophylaxis in medical patients. Clin Cornerstone. 2005;7 (4):16-22. Al Khadra AS, Salem DN, Rand WM et al. Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1998;31 (4):749-753. Connolly S, Pogue J, Hart R et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367 (9526):1903-1912. Cleland JG, Coletta AP, Lammiman M et al. Clinical trials update from the European Society of Cardiology meeting 2005: CARE-HF extension study, ESSENTIAL, C1BIS-III, S-ICD, ISSUE-2, STRIDE-2, SOFA, IMAGINE, PREAMI, SIRIUS-II and ACTIVE. Eur J Heart Fail. 2005;7 : 1070-1075.

Baker DW, Wright RF. Management of heart failure, IV: anticoagulation for patients with heart failure due to left ventricular systolic dysfunction. JAMA. 1994;272 (20): 1614—1618. Dries DL, Domanski MJ, Waclawiw MA et al. Effect of antithrombotic therapy on risk of sudden coronary death in patients with congestive heart failure. Am J Cardiol. 1997;79 (7):909-913. Carson P, Ziesche S, Johnson G, Colin JN, for the Vasodilator—Heart Failure Trial Study Group. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. J Card Fail. 1999;5

(3):178-187. Шарашидзе MA., Мареев В.Ю., Суворов Ю. И. и др. Влияние изосорбида динитрата на водные пространства организма при хронической недостаточности кровообращения. Тер. архив. 1989;61 (6):119-122. Packer M, O'ConnorCM.GhaliJKetal. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med. 1996;335 (15): 1107-1114. O'Connor CM, Carson PE, MillerABetal. Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. Prospective Randomized Amlodipine Survival Evaluation. Am J Cardiol. 1998;82

(7):881-887. Kanel WB. Plehn J F, Cupples LA. Cardiac failure and sudden death in the Framingham Study. Am Heart J. 1988;115 (4):869—875. Luu M, Stevenson WG, Stevenson LW et al. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation. 1989;80 (6):1675—1680. Мареев В. Ю. Сердечная недостаточность и желудочковые нарушения ритма сердца: проблема лечения. Кардиология. 1996;36 (12):4—12 Hjalmarson A, Goldstein S, Fagerberg В, et al, for the MERIT-HF Study Group. Effects of controlled—release metoprolol on total mortality, hospitalizations, and well— being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). JAMA. 2000;283 (10):1295-302. Poole-Wilson PA, Uretsky BF, Thygesen К et al. Mode of death in heart failure: findings from the ATLAS trial. Heart. 2003;89 (l):42-48. Казей Д. В., Мареев В. Ю., Мухарлямов H. M. Влияние изменений гемодинамики на нарушения ритма сердца: опыт длительного внутривенного введения раствора нитроглицерина больным с сердечной недостаточностью. Бюлл. Веесоюзн. кардиол. научн. Центра. 1989;2:20-25. Казей Д. В., Мареев В. Ю., Агеев Ф.Т. и др. Влияние периферических вазодилататоров на нарушения ритма сердца у больных с хронической сердечной недоста- точ—ностью. Кардиология. 1992;32,(4):30-34 Myerburg RJ, Mitrani R, Interian A et al. Interpretation of outcomes of antiarrhythmic clinical trials: design features and population impact. Circulation. 1998;97 (15): 1514—1521. CIBIS III trial: bisoprolol treatment for CHF leads to 46% reduction in sudden death after one year. Cardiovasc J S Afr. 2006; 17 (5):278. Amiodarone Trials Meta—Analysis Investigators. Effect of prophylactic amiodarone on mortality after acure myocardial infarction and in congestive heart failure: meta — analysis of individual data from 6500 patients in randomized trials. Lancet. 1997;350 (9089):1417—1424. Мареев В.Ю. Возможно ли успешное предотвращение внезапной смерти у больных с хронической сердечной недостаточностью и дисфункцией левого желудочка. Препараты или аппараты? Кардиология. 2004;42 :4— 15. Boutitie F, Boissel JP, Connolly SJ et al. Amiodarone Interaction With —Blockers. Analysis of the Merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) Databases. Circulation. 1999;99 (17):2268- 2275. Bardy GH, Lee KL, Mark DB et al. Amiodarone or an implantable cardioverter—defibrillator for congestive heart failure. N Engl J Med. 2005;352 (3):225-237. Singh SN, Poole J, Anderson J et al. Role of amiodarone or implantable cardioverter/defibrillator in patients with atrial fibrillation and heart failure. Am Heart J. 2006;152(5):974. e7—11. Kovoor P, Eipper V, Byth К et al. Comparison of sotalol with amiodarone for long—term treatment of spontaneous sustained ventricular tachyarrhythmia based on coronary artery disease. Eur Heart J. 1999;20 (5):364-374. Беленков Ю.Н., Сангонова Д.Ф., Агеев Ф.Т, Мареев В. Ю. Сравнительное исследование длительного применения соталола, метоп-ролола и амиодарона у больных с тяжелой сердечной недостаточностью и прогностически опасными желудочковыми нарушениями ритма сердца. Кардиология,1996;36 (1):37—48. MacNeil JH. Review of Sotalol safety in 3257 patients with arrhythmias after 15 June. 1991. Bristol Myers Squibb report, 1993. Data on file. Stevenson WG, Stevenson LW. Atrial fibrillation rn heart failure. N Engl J Med. 1999;341 (12):910—911. Dries DL, Exner DV, Gersh BJ et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SO LVD trials: Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1998;32

(3):695-703. Pardaens K, Van Cleemput J, Vanhaecke J, Fagard RH. Atrial fibrillation is associated with a lower exercise capacity in male chronic heart failure patients. Heart. 1997;78 (6):564—568. Fuster V Ryden LE, Asinger RW et al. ACC/AHA/ ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American

Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur Heart J. 2001 ;22 (20):1S52—1923. Wyse DG, Waldo AL, DiMarco JP et al. The Atrial Fibrillation Follow—up Investigation of Rhythm

Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347 (23): 1825-1833. Van Gelder 1С, Hagens VE, Bosker HA et al. Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation (RACE) Study Group. N Engl J Med. 2002:347 (23): 1834-1840. Boos CJ, Carlsson J, More RS. Rate or rhythm control in persistent atrial fibrillation? QJM. 2003;96(12):881-892. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation in for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996;335 (8):540-546. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic treatment to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999; 131 (7):492-501. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. AFFIRM First Antiarrhythmic Drug Substudy Investigators. J Am Coll Cardiol. 2003;42 (l):20-29. Letelier LM, Udol K, Ena J et al. Effectiveness of amiodarone for conversion of atrial fibrillation to sinus rhythm. Arch Intern Med. 2003:163 (7):777-785. Naccarelli GV, Rinkenberger RL, Dougherty AH, Fitzgerald DM. Adverse effects of amiodarone: pathogenesis, incidence and management. Med Toxicol Adverse Drug Exp. 1989;4 (4):246-253. Greene HL, Graham EL, Werner JA et al. Toxic and therapeutic effects of amiodarone in the treatment of cardiac arrhythmias. J Am Coll Cardiol. 1983;2 (6):1114- 1128. Roy D, Talajic M, Dorian P, Connolly S et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of atrial Fibrillation Investigators. N Engl J Med. 2000;342

(13):913-920. Lundstrom T, Ryden L. Chronic atrial fibrillation. Long—term results of direct current cardioversion.

Acta Med Scand. 1988;223 (1):53—59. Flealey JS, Baranchuk A, Crystal Е et al. Prevention of atrial fibrillation with angiotensin— converting enzyme inhibitors and angiotensin receptor blockers: a metaanalysis. J Am Coll Cardiol. 2005:45 (11): 1832-1839 Matsuda M, Matsuda Y, Yamagishi T et al. Effects of digoxin, propranolol, and verapamil on exercise in patients with chronic isolated atrial fibrillation. Cardiovasc Res. 1991;25 (6):453-457. David D, Segni ED, Klein HO, Kaplinsky E. Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: beneficial effect of an added beta adrenergic blocking agent. Am J Cardiol. 1979;44 (7): 1378-1382. Farshi R, Kistner D, Sarma JS et al. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open—label study of five drug regimens. J Am Coll Cardiol. 1999;33 (2):304-310. Khand AU, Rankin AC, Martin W et al. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol. 2003;42 (11): 1944—1951. Davie AP, Love MP, McMurray JJ. Even low — dose aspirin inhibits arachidonic acid — induced vasodilation in heart failure. Clin Pharmacol Ther. 2000;67 (5):530-537 Guazzi M, Pontone G, Agostoni P.Aspirin worsens exercise performance and pulmonary gas exchange in patients with heart failure who are taking angiotensin — converting enzyme inhibitors. Am Heart J. 1999; 138 (2 Pt 1):254-260. Атауллаханова Д. М., Мареев В. Ю. Влияние лазикса на центральную гемодинамику у больных с сердечной недостаточностью. Тер. Арх. 1980:60(11):109—112. Jhunds PS, Davie AP, McMurray JJ. Aspirin inhibits the acute venodilator response to furosemide in patients with chronic heart failure. J Am Coll Cardiol. 2001;37 (5): 1234—1238. Lindfeld JA, Robertson AD, Lowes BD et al. Aspirin impairs reverse myocardial remodeling in patients with heart failure treated with beta-blockers. J Am Coll Cardiol. 2001 ;38 (7): 1950-1956. A randomized, blinded, trial of clopidogrel vs aspirin in patients at risk of ischemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348 (9038): 1329-1339. Yusuf S, Zhao F, Mehta S. R et al. Effects of clopidogrel in addition to aspirin in patients with

acute coronary syndromes without ST—segment elevation. N Engl J Med. 2001;345 (7):494-502. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trialists of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994 Jan 8;308 (6921):81-106. Cleland JGF. Aspirin: does it have a role in the treatment of heart failure due to ischemic heart disease? In book.: Coats A. (ed) Controversies in the management of heart failure. Churchill Livingstone. 1997:69-82 Hayden M, Pigone M, Phillips et al. Aspirin for primary prevention of cardiovascular events: a summary of the evidence for U.S. Preventive Services Task Force. Ann Intern Med. 2002; 136 (2):161—172 Peterson JG, Topol EJ, Sapp SK et al. Evaluation of the effect of aspirin combined with angiotensin converting enzyme inhibitors in patients with coponary artery disease. Am J Med. 2000; 109 (5):371—377. Latini R, Tognioni G, Maggioni AP et al. Clinical effects of early angiotensin — converting enzyme inhibitor treatment for acute myocardial infarction are similar in presence ana absence of aspirin: systematic overview of individual data from 96712 randomized patients. Angiotensin — converting Enzyme Inhibitor Myocardial Infarction Collaborative Group. J Am Coll Cardiol. 2000;35 (7): 1801-1807. Flather MD, Yusuf S, Kober L et al. Long - term ACE — inhibitor therapy in patients with heart failure or left ventricular dysfunction: a systematic overview of data from individual patients. ACE inhibitor Myocardial Infarction Collaborative Group. Lancet. 2000;355 (9215): 1575-1581. Takkouche, Etminan M, Caamano F et al. Interaction between aspirin and ACE inhibitors: resolving discrepancies using a meta— nalysis. Interaction between aspirin and ACE Inhibitors: resolving discrepancies using a metaanalysis. Drug Saf. 2002;25 (5):373-378. Anderson JL. Hemodynamic and clinical benefits with intravenous milrinone in severe chronic heart failure: results of a multicenter study in the United States. Am Heart J. 1991;121:1956-1964.

Hatzizacharias A, Makris Т Krespi P et al. Intermittent milrinone effect on long-term hemodynamic profile in patients with severe congestive heart failure. Am Heart J. 1999;138:241-246. Uretsky BF, Jessup M, Konstam MAet al, for the Enoximone Multicenter Trial Group. Multicenter trial of oral enoximone in patients with moderate

to moderately severe congestive heart failure: lack of benefit compared with placebo. Circulation. 1990;82 (3):774-780. Feldman AM, Bristow MR, Parmley WW et al, for the Vesnarinone Study Group. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med. 1993;329(3):149-155. Packer M, Carver JR, Rodeheffer RJ, et al, for the PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 1991;325 (21):1468-1475. Applefeld MM, Newman KA, Sutton FJ et al. Outpatient dobutamine and dopamine infusions in the management of chronic heart failure: clinical experience in 21 patients. Am Heart J. 1987;114(3):589-595. Elis A, Bental T, Kimchi O, Ravid M, Lishner M. Intermittent dobutamine treatment in patients with chronic refractory congestive heart failure: a randomized, double—blind, placebo—controlled study. Clin Pharmacol Ther. I998;63 (6):682-685. Caffe MS, Califf RM, Adams KF et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287 (12): 1541-1547. SwedbergK, Cleland J, Dargie Н etal. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 2005;26 (11): 1115-1140. Moiseev VS, Poder P, Andrejevs N et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo—controlled, double-blind study (RUSSLAN). Eur Heart J. 2002;23 (18):1422-1432. Диагностика и лечение фибрилляции предсердий. Российские рекомендации. Разработаны Комитетом экспертов ВНОК. Москва. 2005. Philbin EF, Rocco ТА. Use of angiotensin— converting enzyme inhibitors in heart failure with preserved ventricular systolic function. Am Heart J. 1997;134(2Pt 1):188—195. Карпов Ю.А., Мареев В.Ю., Чазова И. Е. Российские программы оценки эффективности лечения фозиноп- рилом больных с артериальной гипертонией и сердечной недостаточностью. Проект ТРИ Ф (ФЛАГ, ФАСОН, ФАГОТ). Журнал Сердечная Недостаточность. 2003;4 (5):261—265. Cleland JGF. The perindopril in elderly people with chronic heart failure (PEP—CHF) study. Hot Line I Session on XVth World Congress of

Cardiology, Barcelona, 03 September 2006. Klingbeil AU, Schneider M, Martus P et al. A metaanalysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115(l):41-46. Мареев В.Ю., Овчинников А. Г., Агеев Ф. Т., Беленков Ю. Н. Влияние ингибиторов АПФ и антагонистов рецепторов к ангиотензину— II на диастолическую функцию левого желудочка у пациентов с относительно сохранной систолической функцией левого желудочка: результаты исследования «Периндоприл, ИРбесартан и АмлодипиН у болЬных с ХСН и сохраненной систолической функцией левого желудочка (ПИРАНЬя). Журнал Сердечная Недостаточность. 2005;6 (1):4—14. Bergstrom A, Anersson В, Ender M et al. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler— echocardiographic study (SWEDIC). Eur J Heart Fail. 2004;6(4):453-461. The Danish Study Group on Verapamil in Myocardial Infarction. Secondary prevention with verapamil after myocardial infarction. Am I Cardiol. 1990;66 (21):33T— 401. Lopez B, Querejrta R, Gonzalez A et al. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol. 2004;43 (ll):2028-2035. Ali Ahmed, Rich MW, Love ТЕ et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J. 2006:27 (2):178-186. Рекомендации Всероссийского научного общества специалистов по клинической электрофизиологии, аритмологии и кардиостимуляции по проведению клинических электрофизиологических исследований, катетерной абляции и имплантации антиаритмических устройств. http://cardio.tomsk. ru/recom. pdf. European Heart Rhythm Association; Heart Rhythm Society; Zipes DP, Camra AJ, Borggrefe M et al. ACC/ AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death—executive summary. J Am Coll Cardiol. 2006;48 (5): e247-346. BristowM, Saxon L, BoehmerJetal. Comparison of Medical Therapy, Pacing and Defibrillation

in Heart Failure (COMPANION) Investigators. Cardiac— resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004 May 20;350(21):2140-2150. Cleland J, Daubert J, Erdmann E et al. Cardiac Resynchronization — Heart Failure (CARE— HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352 (15): 1539-1549. Abraham W, Young J, Leon A et al. Multicenter InSync ICD II Study Group. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. Circulation. 2004;110 (18):2864-2868. Lee D, Green L, Liu P et al. Effectiveness of implantable defibrillators for preventing arrhythmic events and death: a meta-analysis. I Am Coll Cardiol. 2003;41 (9): 1573— 1582. A comparison of antiarrhythmic—drag therapy with implantable defibrillators in patients resuscitated from near—fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med. 1997;337 (22): 1576—1583. Kadish A, Dyer A, Daubert J et al. Prophylactic

defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350(21):2151- 2158. Moss A, Hall W, Cannotn D et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335 (26): 1933-1940. Buxton A, Lee K, Fisher J et al. A randomized study of prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999;341 (25): 1882-1890. Moss A, Zareba W, Hall W et al. Prophylactic implantation of a defiblirillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346 (12):877-883. Rose EA, Gelijns AC, Moskowitz AJ. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med. 2001; 345 (20):1435-1443.

РАЗДЕЛ V

Диагностика и лечение больных острым инфарктом миокарда с подъемом сегмента ST ЭКГ

Москва 2009

<< | >>
Источник: Оганов Р.Г.. Всероссийское научное общество кардиологов Национальные клинические рекомендации. 2009

Еще по теме Литература:

  1. ЛИТЕРАТУРА194
  2. Источники и литература274
  3. Планы семинарских занятийЛитература
  4. Планы семинарских и практических занятийЛитература
  5. СОВЕТСКАЯ ЛИТЕРАТУРА ПО ЛЕТОПИСАНИЮ (1960-1972 ГГ.) А. Н. Казакевич
  6. МНОГОНАЦИОНАЛЬНАЯ ОТЕЧЕСТВЕННАЯ ЛИТЕРАТУРА И ЧИТАТЕЛЬСКИЕ ОРИЕНТАЦИИ
  7. История, язык, литература как формы воображаемой идентификации
  8. ЛИТЕРАТУРА
  9. ЛИТЕРАТУРА НАРОДОВ РОССИИ
  10. СЕРБСКАЯ, ХОРВАТСКАЯ И СЛОВЕНСКАЯ ЛИТЕРАТУРЫ
  11. ЛАТИНОАМЕРИКАНСКАЯ ЛИТЕРАТУРА
  12. КУЛЬТУРНЫЙ ФОН ВЕДИЙСКОЙ ЛИТЕРАТУРЫ
  13. Ренессансы языка, литературы и изобразительного искусства
  14. СПИСОК ИСПОЛЬЗОВАННОЙ ЛИТЕРАТУРЫ Литература на русском языке